Compile Data Set for Download or QSAR
maximum 50k data
Found 25 Enz. Inhib. hit(s) with all data for assayid = 1 entry = 660
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  2.86nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  44.3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  58.5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285849((2S,6R,11R)-3-(Cyclopropylmethyl)-8-{2-[2-(2-metho...)
Affinity DataKi:  203nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  494nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285847((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataKi:  549nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285816((2S, 6R, 11R)-3-(Cyclopropylmethyl)-8-({2-[2-(2-me...)
Affinity DataKi:  619nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285848((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataKi:  769nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  955nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  1.06E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285851((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataKi:  1.40E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  1.81E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285850((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataKi:  2.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  3.92E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  7.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataIC50:  5.60nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataIC50:  8.40nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285849((2S,6R,11R)-3-(Cyclopropylmethyl)-8-{2-[2-(2-metho...)
Affinity DataIC50:  879nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285847((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataIC50:  2.38E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285816((2S, 6R, 11R)-3-(Cyclopropylmethyl)-8-({2-[2-(2-me...)
Affinity DataIC50:  2.68E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285848((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataIC50:  3.33E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285851((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataIC50:  6.08E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285850((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataIC50:  1.28E+4nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent